

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

KINTOR PHARMA COLLABORATES WITH ETANA TO COMMERCIALISE PROXALUTAMIDE FOR THE TREATMENT OF COVID-19 IN INDONESIA

This is a voluntary announcement issued by Kintor Pharmaceutical Limited (the “**Company**”, and together with its subsidiaries, the “**Group**” or “**Kintor Pharma**”) to update its shareholders and potential investors on the latest business advancement of the Company.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that on 25 August 2021, the Company entered into a licensing agreement (the “**Licensing Agreement**”) with PT Etana Biotechnologies Indonesia (“**Etana**”), an Indonesia-based biotechnology company with a dedicated focus on the manufacturing and commercialisation of biologics in the oncology space for the Southeast Asian market, in relation to the commercialisation of proxalutamide for the treatment of COVID-19 in Indonesia.

Pursuant to the Licensing Agreement, Kintor Pharma will receive from Etana upfront and milestone payments, in addition to the economic benefit relating to the sales from the launch of proxalutamide in Indonesia, which is in line with the industry practice.

Proxalutamide is a new-generation androgen receptor (AR) antagonist developed by Kintor Pharma. Proxalutamide is currently undergoing two registered phase III multi-regional clinical trials (“**MRCT**”) for the treatment of COVID-19 patients with mild to moderate symptoms, and one registered phase III MRCT for COVID-19 inpatients, in various countries and regions including the United States, South America (including Brazil), Europe and Asia. In July 2021, Kintor Pharma was granted an emergency use authorisation (EUA) following which proxalutamide has been used to treat hospitalised COVID-19 patients in certain hospitals in Paraguay. This is the first EUA obtained for proxalutamide globally. On 14 July 2021, Kintor Pharma entered into a licensing agreement with Shanghai Fosun pharmaceutical Development Ltd. on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries. Please refer to the announcements of the Company dated 15 July 2021 and 16 July 2021, respectively, for further information.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that proxalutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company .

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 25 August 2021

As at the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purposes only*